Dupilumab (Dupixent®) for severe atopic dermatitis in children aged 6 months to 6 years old. HTA ID: 23042

Assessment Status Rapid Review Complete
HTA ID 23042
Drug Dupilumab
Brand Dupixent®
Indication Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 21/07/2023
Rapid review completed 01/09/2023
Rapid review outcome A full HTA is not recommended. The NCPE recommends that dupilumab not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. March 2025